# Pancreatic Cystic Lesions

## Overview and Classification

### Epidemiology

Incidental pancreatic cysts are identified in 2 to 45% of cross-sectional imaging studies, with the prevalence increasing with both age and imaging frequency. MRI detects more cysts than CT, with a prevalence approaching 10% at age 70 on MRI. The majority of these cysts are benign or carry low risk, and the central clinical challenge lies in identifying the minority with malignant potential.

### Classification

| Cyst Type | Malignant Potential | Demographics | Location | Duct Communication | CEA | GNAS | Key Feature |
|---|---|---|---|---|---|---|---|
| MD-IPMN | High (40-92%) | Elderly, M=F | Any | Yes (main duct ≥5 mm) | High (>192) | + (60-70%) | Highest malignancy risk |
| BD-IPMN | Low-moderate (6-8% HGD/cancer) | Elderly, M=F | Any | Yes (side branches) | High (>192) | + (60-70%) | Most common incidental cyst |
| MCN | Moderate (15-18%) | Women (95%), age 40-50 | Body/tail (>90%) | No | High (>192) | Absent | Ovarian-type stroma |
| SCA | Virtually none (<1%) | Women, age 60-70 | Any | No | Low (<5) | Absent | Microcystic "honeycomb," central scar |
| Pseudocyst | None | Any (pancreatitis history) | Any | Variable | Low | Absent | Very high amylase (>250, often >5000) |
| SPN | Low (10-15%) | Young women (90%), age 25-35 | Any | No | Variable | Absent | Nuclear beta-catenin; >95% 5-year survival |
| Cystic NET | Follows NET behavior | Any | Any | No | Low | Absent | Chromogranin A+, synaptophysin+ |

Pancreatic cystic lesions are broadly classified based on their malignant potential. Mucinous cysts, which carry malignant potential, include intraductal papillary mucinous neoplasms and mucinous cystic neoplasms. Non-mucinous cysts, which are typically benign, include serous cystadenoma, pseudocyst, and solid pseudopapillary neoplasm. Additional cystic lesions include lymphoepithelial cysts, acinar cell cystadenomas, cystic neuroendocrine tumors, congenital cysts, and retention cysts.

## Intraductal Papillary Mucinous Neoplasm (IPMN)

### Types

Main duct IPMN is defined by dilation of the main pancreatic duct to 5 mm or greater without another identifiable cause of obstruction. It carries the highest malignancy risk, with 40 to 92% of resected specimens harboring high-grade dysplasia or invasive carcinoma. Branch duct IPMN involves cystic dilation of side branches that communicate with the main pancreatic duct and carries a lower overall malignancy risk of 15 to 25%, with high-grade dysplasia or invasive carcinoma found in 6 to 8% of resected specimens. Mixed-type IPMN demonstrates features of both main duct and branch duct involvement and is managed as main duct IPMN.

### Histologic Subtypes (Epithelial Lining)

The gastric subtype is the most common lining of branch duct IPMN, is positive for MUC5AC and negative for CDX2, and carries the lowest malignancy risk. The intestinal subtype, most common in main duct IPMN, is positive for MUC2 and CDX2, progresses to colloid carcinoma, and has a better prognosis when invasive compared with other subtypes. The pancreatobiliary subtype is positive for MUC1, progresses to tubular adenocarcinoma, and carries the worst prognosis when invasive. The oncocytic subtype is rare and typically indolent.

### Molecular Features

KRAS mutations are present in more than 90% of IPMNs and mucinous cystic neoplasms. GNAS mutations are found in 60 to 70% of IPMNs but are absent in MCNs, serving as a key molecular distinguishing feature. The molecular progression sequence involves initial KRAS and GNAS mutations, followed by RNF43 alterations, and then SMAD4, TP53, and CDKN2A mutations in the transition to high-grade dysplasia and invasive carcinoma.

### Risk Stratification — AGA (2015) and ACG/Fukuoka Guidelines (Revised 2017)

#### High-Risk Stigmata (Indication for Surgery if Fit)

High-risk stigmata that warrant surgical resection in medically fit patients include obstructive jaundice caused by a cystic lesion in the pancreatic head, an enhancing mural nodule measuring 5 mm or larger within the cyst, main pancreatic duct dilation to 10 mm or greater, and cytology positive for high-grade dysplasia or malignancy.

#### Worrisome Features (Indication for EUS)

Worrisome features that should prompt EUS evaluation include a cyst measuring 3 cm or larger, an enhancing mural nodule smaller than 5 mm, thickened or enhancing cyst walls, main pancreatic duct measuring 5 to 9 mm, an abrupt change in duct caliber with upstream pancreatic atrophy, lymphadenopathy, elevated CA 19-9, and a cyst growth rate of 5 mm or more over 2 years.

<image>A risk stratification diagram for pancreatic cystic lesions management based on the revised Fukuoka/International Consensus Guidelines. Start at top with "Pancreatic cyst detected on imaging." First decision: "Main duct dilation >= 5 mm?" If yes, classify as MD-IPMN or mixed-type. If no, classify as BD-IPMN or other cystic lesion. For MD-IPMN: check for high-risk stigmata (MPD >= 10 mm, obstructive jaundice, enhancing mural nodule >= 5 mm) -> if present: "Surgery recommended if surgically fit." For BD-IPMN: check size and features. Three pathways: (1) "High-risk stigmata present" -> surgery. (2) "Worrisome features present" (cyst >= 3 cm, MPD 5-9 mm, small mural nodule, wall thickening, lymphadenopathy, growth >= 5 mm/2 years) -> "EUS with FNA" -> based on findings: surgery or surveillance. (3) "No worrisome features, cyst < 3 cm" -> surveillance with MRI/MRCP. Include surveillance intervals in a box: <1 cm: MRI in 2-3 years if no change, lengthen interval; 1-2 cm: yearly x 2, then lengthen if stable; 2-3 cm: EUS in 3-6 months, then alternate MRI/EUS yearly. Use red for surgery pathway, yellow for EUS/further workup, green for surveillance.</image>

### EUS Evaluation and Cyst Fluid Analysis

EUS morphologic evaluation assesses mural nodules (with contrast-enhanced harmonic EUS improving detection), septations, communication with the main pancreatic duct, and wall characteristics. Cyst fluid carcinoembryonic antigen greater than 192 ng/mL has 73% sensitivity and 84% specificity for identifying mucinous cysts (MCN or IPMN), while a level below 5 ng/mL favors serous cystadenoma or pseudocyst. Cyst fluid glucose below 50 mg/dL favors a mucinous cyst and may be as accurate as CEA, as demonstrated in the CHARM study. Cyst fluid amylase greater than 250 U/L is elevated in pseudocysts and IPMNs that communicate with the duct, but is low in MCN and serous cystadenoma.

Cytology has low sensitivity (25 to 50%) but high specificity for mucinous epithelium, high-grade dysplasia, or malignancy; the presence of mucin-producing columnar cells is diagnostic. Molecular markers including KRAS and GNAS mutations confirm mucinous differentiation, while loss of heterozygosity and TP53 or SMAD4 mutations suggest advanced neoplasia.

### Surveillance Protocols

#### ACG 2024 Guidelines

For cysts smaller than 1 cm, MRI should be performed at 1 year, then every 2 years if stable for 5 years, after which discontinuation may be considered if no change has occurred. Cysts of 1 to 2 cm should be followed with MRI every year for 3 years, then every 2 years if stable, with total surveillance duration individualized over 5 to 10 years if stable. Cysts of 2 to 3 cm warrant EUS within 3 to 6 months, followed by alternating EUS and MRI annually. Cysts larger than 3 cm should undergo EUS with fine-needle aspiration, with close surveillance or surgery based on findings and patient factors. Discontinuation of surveillance may be considered for patients who are no longer surgical candidates or after prolonged stability exceeding 5 years in low-risk cysts.

## Mucinous Cystic Neoplasm (MCN)

### Features

Mucinous cystic neoplasms occur almost exclusively in women (95%), with a mean age of 40 to 50 years. They are located in the body and tail of the pancreas in more than 90% of cases and, importantly, do not communicate with the pancreatic duct, a key feature distinguishing them from IPMN. The pathognomonic histologic finding is ovarian-type stroma beneath the mucinous epithelium. Molecularly, KRAS mutations are present in 75%, while GNAS mutations are absent, further distinguishing MCN from IPMN. The overall malignancy risk is 15 to 18%, decreasing to 3 to 5% for cysts smaller than 4 cm without nodules.

### Management

Surgical resection is recommended for all mucinous cystic neoplasms given their malignant potential and the typically young age of the patient population. Distal pancreatectomy, preferably performed laparoscopically, is the standard approach for body and tail lesions. Observation may be considered for small (less than 3 cm), asymptomatic MCNs without worrisome features in patients with high surgical risk.

## Serous Cystadenoma (SCA)

### Features

Serous cystadenomas demonstrate a female predominance, with a mean age of 60 to 70 years. On imaging, they display a characteristic microcystic or "honeycomb" pattern with a central stellate scar, which is calcified in 30% of cases. A "sunburst" calcification pattern is pathognomonic. A macrocystic variant exists that may mimic mucinous cysts, though it is less common and features larger cyst compartments. On EUS-guided fine-needle aspiration, cyst fluid demonstrates low CEA and low amylase, with glycogen-rich cuboidal cells on cytology. An association exists with von Hippel-Lindau syndrome, in which multiple SCAs may be accompanied by renal cell carcinoma, hemangioblastomas, and pheochromocytoma.

### Management

Serous cystadenomas have virtually no malignant potential, with serous cystadenocarcinoma occurring in less than 1% of cases. Observation is appropriate for most patients. Surgery is considered only for symptomatic lesions (mass effect or growth), diagnostic uncertainty, or cysts that are very large (greater than 4 cm and growing). No surveillance is needed once the diagnosis has been made with confidence.

## Solid Pseudopapillary Neoplasm (SPN)

### Features

Solid pseudopapillary neoplasms occur predominantly in young women (90%), with a mean age of 25 to 35 years. They are rare tumors that present as large (mean 6 to 8 cm), well-encapsulated, mixed solid-cystic masses. They carry low-grade malignant potential, with 10 to 15% demonstrating malignant features such as local invasion or metastasis, but the prognosis following resection is excellent, with more than 95% five-year survival. The hallmark immunohistochemical finding is nuclear expression of beta-catenin.

### Management

Surgical resection is recommended for all solid pseudopapillary neoplasms, including those that are small and incidentally discovered, as resection is curative in the vast majority of cases. Even in the setting of metastatic disease, the prognosis remains favorable with an aggressive surgical approach.

## Cystic Neuroendocrine Tumor

Cystic variants account for 10 to 17% of pancreatic neuroendocrine tumors. They are typically thick-walled and unilocular or oligolocular. EUS-guided fine-needle aspiration is positive for neuroendocrine markers including chromogranin A and synaptophysin. Management follows pancreatic neuroendocrine tumor guidelines, with surgery indicated for functional tumors and those larger than 2 cm.

## Pseudocyst

Pseudocysts are encapsulated fluid collections without solid debris that complicate acute or chronic pancreatitis. A history of pancreatitis is typically present. Cyst fluid amylase is elevated (greater than 250 U/L, often exceeding 5000 U/L), CEA is low, and there is no mucinous epithelial lining, as the cyst wall is composed of fibrous tissue. Drainage is indicated only when pseudocysts are symptomatic (causing pain, obstruction, or infection) or measure greater than 6 cm and are enlarging. EUS-guided cystogastrostomy with a lumen-apposing metal stent is the preferred drainage approach.

<image>A cyst fluid analysis comparison table for the major pancreatic cystic lesions. Create a visual grid/table with columns for: IPMN, MCN, SCA, Pseudocyst, and Cystic NET. Rows for: CEA level (with numerical range and color gradient: red for high >192, green for low <5), Amylase (high or low with values), Glucose (high or low with threshold <50 mg/dL), Cytology findings (mucinous columnar cells, glycogen-rich cuboidal cells, inflammatory cells, neuroendocrine cells), Molecular markers (KRAS, GNAS mutations), Viscosity (high/mucoid or low/serous). Include a diagnostic pearl box: "CEA >192 = mucinous (73% sensitivity, 84% specificity); Glucose <50 = mucinous (comparable accuracy to CEA); Amylase >250 suggests ductal communication (pseudocyst, IPMN); GNAS mutation present = IPMN (not MCN)." Use color coding to make the table easy to scan at a glance. Add small representative imaging appearances (microcystic honeycomb for SCA, multilocular for IPMN, thick-wall unilocular for MCN, homogeneous fluid for pseudocyst) above each column header.</image>

## Special Considerations

### When to Operate vs Surveil

Surgery is appropriate when high-risk stigmata are present, when there is confirmed or suspected high-grade dysplasia or malignancy, for MCN in a good surgical candidate, for solid pseudopapillary neoplasm, for symptomatic cysts, and when diagnostic uncertainty remains after complete workup. Surveillance is appropriate for branch duct IPMN without worrisome features, confidently diagnosed serous cystadenoma, asymptomatic pseudocyst, and patients who are not surgical candidates. Shared decision-making should incorporate patient preferences, surgical risk, life expectancy, and the psychological burden of ongoing surveillance.

### Multifocal IPMN

Multifocal IPMNs are common, occurring in 20 to 40% of cases, reflecting a field defect of the pancreatic ductal epithelium. Management should be guided by the highest-risk individual lesion. After surgical resection, continued surveillance of the remnant pancreas with annual MRI/MRCP and EUS is essential, as the risk of new primary pancreatic ductal adenocarcinoma in the remnant is approximately 1% per year.

### IPMN and Concomitant PDAC

The risk of a separate pancreatic ductal adenocarcinoma distinct from IPMN-associated carcinoma is 2 to 10%. These cancers often arise at a site distant from the IPMN, reinforcing the importance of whole-pancreas surveillance rather than focusing exclusively on the known cystic lesion.

## Key Clinical Pearls
- Main duct IPMN (MPD >= 10 mm) has 40-92% malignancy risk — surgical resection recommended for all fit patients
- GNAS mutations are present in 60-70% of IPMNs but NOT in MCNs — useful for molecular distinction
- Cyst fluid glucose <50 mg/dL is emerging as an accurate and inexpensive alternative to CEA for identifying mucinous cysts
- Serous cystadenoma is virtually benign — confident diagnosis by imaging (microcystic honeycomb with central scar) avoids unnecessary surgery
- MCNs do NOT communicate with the pancreatic duct and occur almost exclusively in women (body/tail) — distinguish from BD-IPMN
- After resection of IPMN, continued surveillance of the remnant pancreas is mandatory — risk of metachronous IPMN and de novo PDAC is 1% per year
- Solid pseudopapillary neoplasms in young women should be resected — excellent prognosis even with metastatic disease
- Discontinuation of cyst surveillance is appropriate for patients who are no longer surgical candidates or after prolonged stability in low-risk cysts

## References
1. Elta GH, et al. ACG Clinical Guideline: Diagnosis and Management of Pancreatic Cysts. *Am J Gastroenterol*. 2024;119(11):2199-2220.
2. Tanaka M, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. *Pancreatology*. 2017;17(5):738-753.
3. Vege SS, et al. American Gastroenterological Association Institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. *Gastroenterology*. 2015;148(4):819-822.
4. Springer S, et al. A combination of molecular markers and clinical features improve the classification of pancreatic cysts. *Gastroenterology*. 2015;149(6):1501-1510.
5. Park WG, et al. Cyst fluid glucose is a simple, accurate, and low-cost test to diagnose mucinous pancreatic cysts (CHARM study). *Gastroenterology*. 2021;161(6):1882-1896.